Showing 3481-3490 of 4116 results for "".
Humphries to Valeant, Restylane Line Expands, 2016 Highlights
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-humphries-to-valeant-restylane-line-expands-2016-highlights/18709/The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needsRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20835/A History of Phlebology – Warts and All, Part 2 of 3
https://practicaldermatology.com/topics/general-topics/a-history-of-phlebology--warts-and-all-part-2-of-3/20862/Are You Down with QPP?
https://practicaldermatology.com/topics/practice-management/are-you-down-with-qpp/20853/Moving Beyond PASI
https://practicaldermatology.com/topics/psoriasis/moving-beyond-pasi/20883/Making the case for BSA x PGA and more in psoriasis assessment and evaluation.Staying Ahead of the Curve
https://practicaldermatology.com/topics/practice-management/staying-ahead-of-the-curve/20882/Is your practice website responsive enough?5 Ideas to Strengthen Your Dermatology Mobile Marketing
https://practicaldermatology.com/topics/practice-management/5-ideas-to-strengthen-your-dermatology-mobile-marketing/20873/Mobile search has made dramatic strides in recent years. It is time to boost your dermatology online exposure through mobile marketing.What Patients Want to Hear
https://practicaldermatology.com/topics/practice-management/what-patients-want-to-hear/20872/The five most influential components of successful telephone conversions.“Thanks, Doc, but we don't need you anymore…”
https://practicaldermatology.com/topics/practice-management/thanks-doc-but-we-dont-need-you-anymore/20870/Investment Alternatives to Reduce Portfolio Risk
https://practicaldermatology.com/topics/practice-management/investment-alternatives-to-reduce-portfolio-risk/20901/